HemaMax

BIOLOGICAL2 trials

Sponsors

Neumedicines Inc.

Conditions

Hematopoietic Syndrome Due to Acute Radiation Syndrome

Phase 1

Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure

CompletedNCT01742221

Neumedicines Inc.Hematopoietic Syndrome Due to Acute Radiation Syndrome

Start: 2012-08-31End: 2012-12-31Updated: 2018-11-16

Phase 2

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

CompletedNCT02343133

Neumedicines Inc.Hematopoietic Syndrome Due to Acute Radiation Syndrome

Start: 2015-01-31End: 2016-04-30Updated: 2018-11-16

Related Papers

Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.

2014-04-1123 citations